ClinicalTrials.gg
Active, not recruitingNCT07866508Updated Oct 8, 2026

Comparison of Analgesic Efficacy of Intrathecal Bupivacaine Versus Bupivacaine Plus Dexmedetomidine in Patients Undergoing Orthopedic Surgeries.

An Early Phase 1 interventional study of Dexmedetomidine plus Hyperbaric Bupivacaine and Hyperbaric bupivacaine % 0.5 in Postoperative Pain, Pain and Orthopaedic Surgery, sponsored by Sheikh Khalifa Bin Zayed Al Nahyan Combined Military Hospital Muzaffarabad. Active, not recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Sheikh Khalifa Bin Zayed Al Nahyan Combined Military Hospital Muzaffarabad · Early Phase 1, Interventional, and Supportive care

Updated Oct 8, 2026Newly registeredGo to Updates ↓
Phase
Early Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Clinical Trial Overview: Intrathecal Bupivacaine vs. Bupivacaine + Dexmedetomidine Primary Objective

Duration of Analgesia:** To compare the mean duration of postoperative pain relief between hyperbaric bupivacaine alone versus bupivacaine combined with dexmedetomidine in adults undergoing elective lower-limb orthopedic surgeries.

Secondary Objectives

Block Characteristics:** Compare the exact onset and duration of both sensory and motor blockade.

Safety Profile:** Monitor and compare hemodynamic stability, focusing on side effects like hypotension (low blood pressure) and bradycardia (low heart rate).

Study Design \& Framework

Design:** Prospective, randomized, double-blind, parallel-group controlled clinical trial.

Setting:** SKBZ-AK CMH, Muzaffarabad, Azad Kashmir. Sample Size:** Total of 80 patients divided into two equal groups (Group B = 40, Group BD = 40) using consecutive sampling.

Intervention \& Protocol Breakdown

Patients will be randomly and blindly assigned to one of two distinct groups, receiving a single intrathecal (spinal) injection:

  • Group \| Local Anesthetic Component \| Adjuvant / Control Component \|
  • --- \| --- \| --- \|
  • **Group B (Control)** \| 15 mg of 0.5% Hyperbaric Bupivacaine \| 0.5 mL Normal Saline \|
  • **Group BD (Study)** \| 15 mg of 0.5% Hyperbaric Bupivacaine \| 10 µg Dexmedetomidine \|

Participant Journey \& Data Collection

To maintain strict data integrity and satisfy the protocol requirements, enrolled patients will undergo a structured timeline from screening to a 24-hour postoperative monitoring phase:

Screening \& Consent:** Pre-Anaesthesia Clinic. Recruit patients meeting strict criteria (Aged 18-60, ASA I/II, BMI 18.5-29.9 kg/m²) and obtain informed written consent while recording baseline characteristics.

Randomized Drug Delivery:** Intraoperative Phase. Administer the concealed study drug at the L3-L4 or L4-L5 space. Assess the immediate onset of sensory block at the T10 dermatome and monitor vital signs every 5 to 10 minutes.

3. **Postoperative Monitoring:** First 24 Hours. Track regression of sensory and motor blocks using the Modified Bromage Scale. Log the exact time to first rescue analgesia request (triggered when pain score NRS is 4 or greater) and monitor for safety endpoints.

> **Operational Target:** The primary hypothesis hinges on a significant extension of the time window before the first rescue analgesia is requested. International data in obstetric fields suggests a profound extension, but this trial establishes direct clinical evidence for orthopedic lower-limb procedures.

Read the detailed description

TITLE Comparison of analgesic efficacy of Intrathecal Bupivacaine versus Bupivacaine plus Dexmedetomidine in Patients Undergoing Orthopedic Surgeries.

INTRODUCTION Spinal anesthesia is the preferred regional anesthesia technique for lower-limb orthopedic surgeries owing to its rapid onset, profound sensory and motor blockade, cost-effectiveness, and minimal systemic side effects. Hyperbaric bupivacaine remains the most commonly used local anesthetic for spinal anesthesia; however, its duration of postoperative analgesia is limited to approximately 150-210 minutes, frequently requiring early administration of systemic analgesics in the recovery period. 1, 2 Dexmedetomidine, a highly selective α₂-adrenergic agonist, has been widely studied as an intrathecal adjuvant because of its analgesic and sympatholytic properties. Previous studies have demonstrated that the addition of dexmedetomidine to hyperbaric bupivacaine significantly shortens the onset of sensory and motor blockade, prolongs sensory and motor regression, reduces postoperative analgesic requirements, and provides better hemodynamic stability with minimal adverse effects, it can eve reduce bupivacaine related cardiac toxicity.3,6 As Local anesthetics alone have short duration of action and patients may need postoperative systemic analgesics and orthopedic surgeries are associated with postoperative pain leading to unsuccessful rehabilitation and suboptimal healing. So adding an adjuvant like dexmedetomidine can significantly reduce post operative pain and use of systemic analgesics leading to better patient recovery and less morbidity 7,8, Patients receiving 10 µg intrathecal dexmedetomidine with 0.5% hyperbaric bupivacaine showed significantly prolonged sensory regression to S1 segment (413±46 minutes vs 163±24 minutes) and motor block regression to Bromage 0 (307±18 minutes vs 145±25 minutes) compared with patients receiving plain bupivacaine alone. The dexmedetomidine group also required less rescue analgesia during the first 12 postoperative hours.2 Despite this strong and consistent international evidence published in the last five years in surgeries related to gynae and obs, there is still a lack of data in orthopedic surgeries. 9,10 The present study is therefore designed to provide evidence on the analgesic efficacy, block characteristics, and safety of adding 10 µg dexmedetomidine to intrathecal hyperbaric bupivacaine in adult patients undergoing elective lower-limb orthopedic surgery.

OBJECTIVES Primary Objective To compare the mean duration of postoperative analgesia of intrathecal hyperbaric bupivacaine alone versus bupivacaine plus dexmedetomidine in adult patients undergoing elective lower limb orthopedic surgeries.

Secondary Objectives To compare the sensory and motor blockade and hemodynamic side-effect profile of both groups.

OPERATIONAL DEFINITIONS

  1. Duration of Analgesia: Time from intrathecal injection to the first request for rescue analgesia or when the Numeric Rating Scale (NRS) score becomes ≥ 4.
  2. Duration of Sensory Block: Time from intrathecal injection to two-segment regression of sensory level or regression to the L1 dermatome (assessed by loss of pinprick sensation).
  3. Onset of Sensory Block: Time from intrathecal injection to reach sensory block at the T10 dermatome.
  4. Duration of Motor Block: Time from intrathecal injection to Modified Bromage Score = 0 (full recovery).
  5. Hypotension: Fall in mean arterial pressure (MAP) > 20% from baseline.
  6. Bradycardia: Heart rate \< 50 beats/min.
  7. Elective Lower Limb Orthopaedic Surgery: Surgical procedures involving the femur, tibia, fibula, or ankle joints, planned in advance and expected to last between 60 and 150 minutes, requiring sensory blockade at or above the T10 dermatome.

HYPOTHESIS Addition of 10 µg dexmedetomidine to intrathecal hyperbaric bupivacaine significantly prolongs the mean duration of postoperative analgesia compared to hyperbaric bupivacaine alone in adult patients undergoing elective lower limb orthopaedic surgeries.

Secondary Hypothesis Addition of 10ug of Dexmedetomidine into intrathecal hyperbaric bupivacaine affects sensory and motor blockade and reduces hemodynamic side effects of bupivacaine alone.

MATERIAL AND METHODS Study Design: Prospective, randomized, double-blind, parallel-group controlled clinical trial.

Study Setting: The study will be conducted at SKBZ-AK CMH, Muzaffarabad, Azad Kashmir Duration of Study: The study will be carried out over a period of 03 months after the approval of synopsis.

Sample Size: The sample size was calculated using a two-sided two-sample parallel means comparison formula based on the reference study by Alam et al. evaluating the effectiveness of intrathecal dexmedetomidine in combination with hyperbaric bupivacaine. Using a 95% confidence level, 90% statistical power, and a 1:1 group allocation ratio, the statistical calculation yields a minimal size of 32 patients per group. However, to account for potential dropouts, technical failures of the subarachnoid block, or intraoperative alterations in the surgical plan, the sample size was increased to 40 patients per group (Group B = 40, Group D = 40), making a total sample size of 80 patients.

Sampling Technique: Non-probability, consecutive sampling. Sample Selection

DATA COLLECTION PROCEDURE The study will be performed after taking approval from the ethics review committee of SKBZ-AK CMH Muzaffarabad and CPSP. A total of 80 patients presenting to the pre-anaesthesia clinic, meeting the enrollment criteria, will be recruited in the study after obtaining informed consent of the patients. Patient characteristics like age, gender, weight, height, ASA status, and baseline hemodynamics will be recorded.

Patients will be randomly allocated to either Group B (Control) or Group BD (Study) using computer-generated random numbers with SNOSE allocation concealment. Group B will receive 15 mg of 0.5% hyperbaric bupivacaine plus 0.5 mL normal saline. Group BD will receive 15 mg of 0.5% hyperbaric bupivacaine plus 10 µg dexmedetomidine. The study drug will be prepared by an independent technician to maintain double-blinding.

Standard monitoring will be established and spinal anaesthesia will be performed at L3-L4/L4-L5 space. Onset and duration of sensory and motor blocks will be assessed using pinprick and Modified Bromage Scale. The duration of analgesia will be recorded as the time to the first request for rescue analgesia (NRS ≥ 4). All the patients will be monitored for side effects like hypotension and bradycardia for 24 hours. All the data will be recorded on a pre-designed proforma.

DATA ANALYSIS PROCEDURE Data will be analyzed using Statistical Package for the Social Sciences (SPSS) version 26.0. Descriptive statistics will be calculated for all variables. Continuous variables-including age, weight, height, BMI, onset of sensory block, duration of sensory and motor blockade, and the primary outcome (duration of postoperative analgesia)-will be assessed for normality using the Shapiro-Wilk test.

Normally distributed continuous data will be presented as Mean ± SD and compared between the two groups using the Independent samples t-test. Non-normally distributed data will be presented as Median (Interquartile Range) and analyzed using the Mann-Whitney U test. Hemodynamic trends (Heart Rate, MAP) and pain scores (NRS) recorded at multiple time intervals will be analyzed using Repeated Measures ANOVA to evaluate differences over time between the groups.

Categorical data, including Gender, ASA Status, and the incidence of adverse events (hypotension and bradycardia), will be expressed as frequencies and percentages, and compared using the Chi-square test or Fisher's exact test where cell counts are less than 5. A p-value of \< 0.05 will be considered statistically significant for all analyses.

Research Performa

Name:__________________ Age:_______________ Gender:_________________ Phone:_______________ Weight:_________________ Height:_______________ BMI___________ Level of Block_____________ ASA Class______________ Type of Surgery ___________

Time Pulse SBP Diastolic MAP SPO² Pre SAB 5 min 10 min 20 min 30 min 40 min 50 min 60 min 70 min 80 min 90 min 100 min 110 min 120 min

Time NRS Sensory Block Bromage score RASS Onset

1st hour 2nd hour 3rd hour 4th hour 5th hour 6th hour 8th hour 10th hour 12th hour

  1. st Hour
  2. nd Hour
  3. rd Hour
  4. th Hour
  5. th Hour
  6. th Hour

8th Hour

10th Hour

12th Hour

Comments (If any):

Sign and Stamp:_______________________. Date:________________

02

Conditions studied

  • Postoperative Pain
  • Pain
  • Orthopaedic Surgery
  • Anesthesia, Spinal

Keywords

  • Intrathecal dexmedetomidine
  • Hyperbaric bupivacaine
  • Spinal anesthesia
  • Postoperative analgesia
  • Lower limb surgery
  • Modified Bromage Score
  • Sensory and motor blockade
03

In context

Pain, Postoperative

5,224 studies on the registry are indexed under Pain, Postoperative; 1,154 are open to participants now.

This study's planned enrollment of 80 is close to the median of 75 across 4,457 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Sheikh Khalifa Bin Zayed Al Nahyan Combined Military Hospital Muzaffarabad is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients of both genders.
  2. Age between 18 and 60 years.
  3. American Society of Anesthesiologists (ASA) physical status I and II.
  4. Scheduled for elective lower limb orthopaedic surgeries (e.g., femur, tibia, or fibula fractures) under spinal anaesthesia.
  5. Body Mass Index (BMI) between 18.5 and 29.9 kg/m².

Exclusion criteria

Exclusion Criteria:

  1. Patients refusing spinal anaesthesia.
  2. Patients with absolute contraindications to regional anaesthesia (e.g., localized infection at the puncture site, coagulopathy, raised intracranial pressure).
  3. Patients with a documented history of hypersensitivity or allergy to bupivacaine or dexmedetomidine.
  4. Patients currently on chronic opioid therapy or α₂-adrenergic agonists.
  5. Patients with severe systemic diseases, including severe cardiac (NYHA Class III/IV), hepatic, or renal impairment.
  6. Pregnant females (confirmed via history and urine pregnancy test).
05

Study design

Phase
Early Phase 1
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Group B

    Drug: Hyperbaric bupivacaine % 0.5

  • Experimental
    Group BD

    Drug: Dexmedetomidine plus Hyperbaric Bupivacaine

Interventions

  • DrugDexmedetomidine plus Hyperbaric Bupivacaine

    Drug page: Dexmedetomidine

    Intervention Description: Administration of 15 mg of 0.5% hyperbaric bupivacaine combined with 10 µg of dexmedetomidine via intrathecal injection for spinal anesthesia.

    Also known as: Intrathecal Dexmedetomidine

  • DrugHyperbaric bupivacaine % 0.5

    Intervention Description: Administration of 15 mg of 0.5% hyperbaric bupivacaine via intrathecal injection for spinal anesthesia.

06

What researchers measure

Primary outcomes

  1. Duration of Postoperative Analgesia

    Assessed using the Numeric Rating Scale (NRS). It is defined as the time from the intrathecal injection to the first request for rescue analgesia or when the NRS score becomes ≥ 4

    Time frame: Up to 12 hours post-injection

07

Study locations

1 site
  • SKBZ AK CMH Muzaffarabad
    Muzaffarabad, Azad Kashmir 13100, Pakistan
08

References and documents

Publications

  • Mohamed T, Susheela I, Balakrishnan BP, Kaniyil S. Dexmedetomidine as Adjuvant to Lower Doses of Intrathecal Bupivacaine for Lower Limb Orthopedic Surgeries. Anesth Essays Res. 2017 Jul-Sep;11(3):681-685. doi: 10.4103/aer.AER_243_16. PubMed 28928571 ↗
  • Kumar S, Choudhury B, Varikasuvu SR, Singh H, Kumar S, Lahon J, Saikia D. A Systematic Review and Meta-analysis of Efficacy and Safety of Dexmedetomidine Combined With Intrathecal Bupivacaine Compared to Placebo. Cureus. 2022 Dec 12;14(12):e32425. doi: 10.7759/cureus.32425. eCollection 2022 Dec. PubMed 36644042 ↗
  • Farmawy MSE, Mowafy SMS, Wahdan RA. Epidural nalbuphine versus dexmedetomidine as adjuvants to bupivacaine in lower limb orthopedic surgeries for postoperative analgesia: a randomized controlled trial. BMC Anesthesiol. 2023 Dec 6;23(1):401. doi: 10.1186/s12871-023-02348-x. PubMed 38057695 ↗
  • Giaccari LG, Coppolino F, Aurilio C, Pace MC, Passavanti MB, Pota V, Sansone P. Is intrathecal bupivacaine plus dexmedetomidine superior to bupivacaine in spinal anesthesia for a cesarean section? A systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2024 Aug;28(15):4067-4079. doi: 10.26355/eurrev_202408_36638. PubMed 39194198 ↗
  • Jin Z, Xia F, Lin T, Cai Y, Chen H, Wang Y. Dexmedetomidine may decrease the bupivacaine toxicity to heart. Open Med (Wars). 2021 Jul 15;16(1):1070-1075. doi: 10.1515/med-2021-0311. eCollection 2021. PubMed 34307889 ↗
  • Khan MK, Hafeez A, Feroze F, Tahir AA, Abbasi S, Faheem MSB, Farooq S. Effect Of Perineural Administration Of Dexmedetomidine With Bupivacaine Versus Bupivacaine Alone In Ultrasound Guided Supraclavicular Block For Upper Extremity Orthopaedic Operations. J Ayub Med Coll Abbottabad. 2023 Jul-Sep;35(3):384-389. doi: 10.55519/JAMC-03-12044. PubMed 38404077 ↗
  • Alam SS, Abbas N, Asgher A, Rafique M; Anees-ur-Rehman; Abid K. Effectiveness Of Intrathecal Dexmedetomidine In Combination With Hyperbaric Bupivacaine For Lower Abdominal Surgeries And Its Postoperative Analgesic Characteristic. J Ayub Med Coll Abbottabad. 2022 Oct-Dec;34(Suppl 1)(4):S936-S939. doi: 10.55519/JAMC-04-S4-10179. PubMed 36550648 ↗
  • Olawin AM, Das JM. Spinal Anesthesia. 2022 Jun 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK537299/ PubMed 30725984 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Oct 2026, 2 months after the start.

Of 71 non-industry phase 1 interventional studies under Pain, Postoperative, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 2 months is below that.

Counting every sponsor, half of 86 studies reached it within 16 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2026
First posted
Oct 8, 2026
StartActual
Aug 1, 2026
Primary completionEst.
Oct 31, 2026
CompletionEst.
Oct 31, 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07866508
Lead sponsor
Sheikh Khalifa Bin Zayed Al Nahyan Combined Military Hospital Muzaffarabad
Responsible party
Abdul Wahab (Anaesthesiologist, Sheikh Khalifa Bin Zayed Al Nahyan Combined Military Hospital Muzaffarabad) — Principal investigator
First posted
Oct 8, 2026
Start date
Aug 1, 2026
Primary completion
Oct 31, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Oct 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion